Phase Ib Dose-Escalation Study of LCL161 in Combination With Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer (SCLC) and Select Gynecologic Malignancies

Trial Profile

Phase Ib Dose-Escalation Study of LCL161 in Combination With Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer (SCLC) and Select Gynecologic Malignancies

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Sep 2017

At a glance

  • Drugs LCL 161 (Primary) ; Topotecan (Primary)
  • Indications Fallopian tube cancer; Gynaecological cancer; Ovarian cancer; Peritoneal cancer; Small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 22 Sep 2017 Planned End Date changed from 1 Aug 2018 to 1 Dec 2018.
    • 22 Sep 2017 Planned primary completion date changed from 27 Jul 2017 to 27 Jul 2018.
    • 13 Apr 2017 Planned primary completion date changed from 1 Mar 2017 to 27 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top